Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Imeglimin in Japanese Subjects With Renal Impairment
jRCT2080224682Phase 1Completed
- Sponsor
- Sumitomo Pharma
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of imeglimin in chronic kidney disease (CKD) (4 arms), sponsored by Sumitomo Pharma. Primary endpoints: Cmax of imeglimin and AUC of imeglimin. Started May 2019; status: completed.
02
Drugs
imeglimin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2080224682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224682.